// IP Marketing video - START// IP Marketing video - END

Meningitis vaccine licensed for use in Europe

Meningitis vaccine licensed for use in Europe

PanARMENIAN.Net - A vaccine to protect children against one of the most common and deadly forms of meningitis has been licensed for use in Europe, BBC News reported.

The Bexsero vaccine licensed by the European Commission is the first to cover meningococcal B meningitis - until now vaccines had protected against only some of the bacterial types involved.

About 1,870 people contract meningitis B each year and one in 10 die.

About a quarter of all survivors of meningitis B are left with life altering after-effects, such as brain damage or limb loss. Children under the age of five are the most at risk from the bacterial infection, which leads to inflammation of the brain and spinal cord.

Experts say the jab is likely to be effective against 73% of the different variations of meningitis B.

A vaccine against the less common meningitis C has been administered since 1999 and is now widely given to babies in the first year of their life.

It has led to a large fall in the number of cases in people under the age of 20.

 Top stories
Jagland cited Armenia as a country that has improved access to minority language education in line with the Council of Europe instruments.
One of the most important destinations of Armenia, the capital city of Yerevan with the imposing Mount Ararat is a sight to see, the article says.
The analysis reveals that Qatar, the United Arab Emirates and Turkey saw the biggest growth of arrivals in the first three months of 2018.
Power is currently in Armenia as she is a member of the Aurora Prize for Awakening Humanity Selection Committee.
Partner news